IRTC:NSD-iRhythm Technologies Inc. (USD)

EQUITY | Medical Devices | NASDAQ Global Market

Last Closing

USD 115.76

Change

+0.76 (+0.66)%

Market Cap

USD 0.62B

Volume

0.41M

Analyst Target

USD 222.50
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

iRhythm Technologies Inc is a commercial-stage digital healthcare company redefining the way cardiac arrhythmias are clinically diagnosed by combining wearable biosensing technology with cloud-based data analytics and machine-learning capabilities.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-03-27 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap
DXCM DexCom Inc

-13.67 (-9.91%)

USD 51.34B
ALGN Align Technology Inc

-1.48 (-0.48%)

USD 23.62B
BRKR Bruker Corporation

+0.38 (+0.47%)

USD 12.93B
SWAV Shockwave Medical Inc

+1.01 (+0.31%)

USD 12.34B
PODD Insulet Corporation

+2.02 (+1.23%)

USD 11.49B
MASI Masimo Corporation

+0.90 (+0.67%)

USD 7.14B
AXNX Axonics Modulation Technologie..

+0.15 (+0.23%)

USD 3.39B
QDEL Quidel Corporation

-0.05 (-0.13%)

USD 3.14B
LIVN LivaNova PLC

+0.43 (+0.78%)

USD 3.02B
IART Integra LifeSciences Holdings

-0.07 (-0.25%)

USD 2.64B

ETFs Containing IRTC

EDOC Global X Telemedicine & D.. 5.93 % 0.00 %

+0.09 (+1.70%)

USD 0.05B
DDOC:F Global X Telemedicine & D.. 5.48 % 0.00 %

+0.07 (+1.70%)

USD 5.32M
EDOC:SW Global X Telemedicine & D.. 5.48 % 0.00 %

+0.12 (+1.70%)

USD 4.92M
EDOC:LSE Global X Telemedicine & D.. 5.39 % 0.00 %

+0.14 (+1.70%)

USD 5.32M
EDOG:LSE Global X Telemedicine & D.. 5.39 % 0.00 %

+0.13 (+1.70%)

USD 5.32M
XMLH:F Legal & General Ucits Etf.. 2.02 % 0.00 %

+0.03 (+1.70%)

USD 0.08B
DOCT:SW L&G Healthcare Breakthrou.. 2.02 % 0.00 %

+0.13 (+1.70%)

USD 0.08B
ROBO:SW L&G ROBO Global Robotics .. 1.77 % 0.00 %

+0.34 (+1.70%)

N/A
SLIM 0.00 % 0.50 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Medical Devices) Market Performance vs. Exchange (NASDAQ Global Market)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 8.15% 68% D+ 69% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 8.15% 68% D+ 69% C-
Trailing 12 Months  
Capital Gain -5.11% 68% D+ 43% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -5.11% 68% D+ 41% F
Trailing 5 Years  
Capital Gain 54.43% 84% B 74% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 54.43% 84% B 71% C-
Average Annual (5 Year Horizon)  
Capital Gain 36.46% 81% B- 88% B+
Dividend Return 36.46% 81% B- 88% B+
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 92.11% 34% F 17% F
Risk Adjusted Return 39.58% 85% B 74% C
Market Capitalization 0.62B 94% A 86% B+

Key Financial Ratios

  Ratio vs. Industry/Classification (Medical Devices) Ratio vs. Market (NASDAQ Global Market)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A
Price/Book Ratio 16.14 12% 7%
Price / Cash Flow Ratio -66.98 98% 94%
Price/Free Cash Flow Ratio -34.97 97% 92%
Management Effectiveness  
Return on Equity -54.86% 52% 31%
Return on Invested Capital -44.18% 45% 24%
Return on Assets -13.93% 60% 30%
Debt to Equity Ratio 16.64% 62% 62%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector